The development of predicting the lung cancer resistance to gemcitabine by the expression levels of RRM1 / 肿瘤研究与临床
Cancer Research and Clinic
;
(6)2000.
Article
in Chinese
| WPRIM
| ID: wpr-543359
ABSTRACT
Gemcitabine is important pyrimidine antimetabolites drug. Ribonucleotide reductase is oneof its targets whose overexpression has been observed in several gemcitabine- resistant cell lines. Meanwhile,the NSCLC patients with high RRM1 expression levels have a relatively poor survival when treated with gem-citabine. To this day, the relationship between RRM1 expression levels in peripheral blood mononuclear cellsand gemcitabine is still uncertain and it deserves further research.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Prognostic study
Language:
Chinese
Journal:
Cancer Research and Clinic
Year:
2000
Type:
Article
Similar
MEDLINE
...
LILACS
LIS